Tenuate
(Diethylpropion)PreclinicalSmall molecule
Tenuate is one of 33 small molecule programs targeting Obesity. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
6
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
392 competitors in Obesity
#DrugCompanyPhaseTrials
1Actemra
RochePreclinical
Avapro
SanofiPreclinical
Amidate
PfizerPreclinical
Adenocard
AstellasPreclinical
Colcrys
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Prometrium
FerringPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Obesity1 trial
Anti-obesity Pharmacotherapy and Inflammation
Active, not recruiting·LLouisiana State University Health Sciences Center in New Orleans··NCT05756764·30 enrolled
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
TENUATE
NDA NDA017669
Jan 1, 1982
TENUATE DOSPAN
NDA NDA012546
Jan 1, 1982
TEPANIL TEN-TAB
NDA NDA017956
Jan 1, 1982
TENUATE
NDA NDA011722
Jan 1, 1982
TENUATE
NDA NDA017668
Jan 1, 1982
TEPANIL
NDA NDA011673
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diethylpropion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]